Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel

View Full Paper
Ask AI
Bookmark
Share

Authors

ATAung M. TunMHMehdi HamadaniTBTimothy Best

Discussion

Loading...

Member takes

Overview

Analysis reveals progression-free survival in follicular lymphoma patients with various comorbidities, suggesting the importance of prior treatments like bendamustine.

Key Points

  • Overall survival rate was 84% at 2 years, indicating sustained response in patients with follicular lymphoma.
  • Cox and logistic regression showed significant associations with comorbidities and prior treatments affecting treatment outcomes.
  • Grade ≥3 cytokine release syndrome occurred in only 4% of patients, suggesting manageable safety profiles for this therapy.
  • Patients receiving bendamustine before treatment demonstrated lower duration of response and progression-free survival compared to those who did not.

Cite This Study

Tun et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db4dhttps://doi.org/10.1182/blood-2025-5356
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study2025
  2. 2Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries2025
  3. 3Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE2025 · 2 citations
  4. 4Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors2025
  5. 5Surrogate endpoints as prognostic factors for long-term outcomes among patients receiving axicabtagene ciloleucel in frontline high-risk large B cell lymphoma2025